Mao et al. reported that knocking down ROR1 could inhibit the growth of DLBCL cells both in vitro and in vivo, highlighting ROR1 as a potential target for DLBCL therapies [177]. Here, ROR1 is linked to diffuse large B-cell lymphoma.